Prosecution Insights
Last updated: April 19, 2026

Examiner: THOMAS, TIMOTHY P

Tech Center 1600 • Art Units: 1611 1614 1628

This examiner grants 26% of resolved cases

Performance Statistics

26.2%
Allow Rate
-33.8% vs TC avg
958
Total Applications
+38.2%
Interview Lift
1280
Avg Prosecution Days
Based on 906 resolved cases, 2023–2026

Rejection Statute Breakdown

1.9%
§101 Eligibility
18.3%
§102 Novelty
38.5%
§103 Obviousness
24.0%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17852032 IONIC LIQUIDS FOR INTERNAL DELIVERY Final Rejection THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
17298060 TOPICAL ANTIMICROBIAL MICROEMULSIONS Final Rejection 3M INNOVATIVE PROPERTIES COMPANY
17715447 COMPOSITION OF AZELAIC ACID HAVING ADIPOSE TRIGLYCERIDE HYDROLYSIS EFFECT Final Rejection Korea University Research and Business Foundation
18870803 EDIBLE FILM AND METHOD FOR MANUFACTURING EDIBLE FILM Non-Final OA NISSHA CO., LTD.
17614267 COMPOSITION AND METHOD FOR ENHANCING SPORE GERMINATION AND BIOLOGICAL EFFICACY Final Rejection DANSTAR FERMENT AG
17358920 STABILIZED FORMULATIONS OF CNS COMPOUNDS Non-Final OA Supernus Pharmaceuticals, Inc.
17098324 MULTIMODAL COMPOSITIONS AND METHODS OF TREATMENT Non-Final OA AQUESTIVE THERAPEUTICS, INC.
16967990 NOVEL PAENIBACILLUS POLYMYXA AND USES THEREOF Final Rejection VALAGRO S.P.A.
17921540 SOLID AND LIQUISOLID FORMULATIONS OF CORALLOPYRONIN A Final Rejection RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT BONN
17633973 ENZYME INHIBITORS Non-Final OA KALVISTA PHARMACEUTICALS LIMITED
17937778 RADIATION SENSITIVITY ENHANCING COMOPOSITION CONTAINING ARIPIPRAZOLE AS ACTIVE INGREDIENT Non-Final OA KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCES
17050462 RADIATION SENSITIVITY ENHANCING COMPOSITION CONTAINING ARIPIPRAZOLE AS ACTIVE INGREDIENT Final Rejection KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCES
17792863 TOPICAL FORMULATION CONTAINING RAPAMYCIN Final Rejection NOBELPHARMA CO., LTD.
16973986 BIO-HERBICIDE BASED ON ESSENTIAL OIL Non-Final OA Université de Liège
18106084 COMPOSITIONS AND METHODS FOR TREATING PAIN AND/OR INFLAMMATION Non-Final OA Neumentum, Inc.
17791700 METHODS OF TREATMENT AND/OR PREVENTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) WITH A COMBINATION OF A BET BROMODOMAIN INHIBITOR AND A DIPEPTIDYL PEPTIDASE 4 INHIBITOR Non-Final OA Resverlogix Corp.
17995220 THE USE OF DIFFUSION ENHANCING COMPOUNDS FOR TREATMENT OF VIRAL AND BACTERIAL INDUCED RESPIRATORY DISEASE Non-Final OA DIFFUSION PHARMACEUTICALS LLC
17790145 TWO-DIMENSIONAL (2D) NANOCOMPOSITE, PREPARATION METHOD, AND USE THEREOF Final Rejection Ningbo Cixi Institute of BioMedical Engineering
17781006 HIGH-STRENGTH MEDICAL FIBER COMPOSITE MATERIAL Non-Final OA CHANGZHOU INSTITUTE OF TECHNOLOGY
17665662 DOSING REGIMEN OF SEDATIVE Final Rejection PAION UK LIMITED
17520763 Photosensitive Dyes and Method of Using Said Dyes Final Rejection STRT LLC
17279555 PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING NITM AND MEDICAL USE THEREOF Final Rejection SHENYANG XiNGQi PHARMACEUTICAL CO., LTD.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month